NCT07077304 EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
| NCT ID | NCT07077304 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Myocarditis |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2025-11-19 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2025-11-19 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms. Diagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights. Given the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and/or cardiac PET in a multicentric international cohort.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Ability to provide informed non-opposition 3. Referred for a CMR and/or nuclear imaging exam AND a suspicion of one of the following ICARDs : 1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies) 2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) 3. Suspected Tako-Tsubo 4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies) 5. Suspected Connective tissue disease with cardiovascular involvement: * Systemic sclerosis * Systemic lupus erythematosus * Antiphospholipid syndrome * Idiopathic inflammatory myopathies * Rheumatoid arthritis, spondylarthritis 6. Suspected Vasculitis with cardiovascular involvement: * Small-vessel vasculitis (ANCA…) * Large vessel vasculitis (Behcet disease, Takayasu…) 7. Suspected Inflammatory disease with cardiovascular involvement: * Sarcoidosis * Still disease Exclusion Criteria: 1. Inability to provide non-opposition 2. History of heart transplant
Frequently Asked Questions
Who can join the NCT07077304 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myocarditis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07077304 currently recruiting?
Yes, NCT07077304 is actively recruiting participants. Visit ClinicalTrials.gov or contact Assistance Publique - Hôpitaux de Paris to inquire about joining.
Where is the NCT07077304 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT07077304 clinical trial?
NCT07077304 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 5,000 participants.